Enrolled (N=43)

Safety population/ mITT population (n=43)

Placebo (n=12)
- Completed dosing (n=11)
- Discontinued (n=1)
- Refused further dosing (not due to AEs) (n=1)

VX-509 100 mg (n=11)
- Completed dosing (n=10)
- Discontinued (n=1)
- Lost to follow-up (n=1)

VX-509 200 mg* (n=10)
- Completed dosing (n=10)
- Discontinued (n=1)
- Lost to follow-up (n=1)

VX-509 300 mg (n=10)
- Completed dosing (n=10)
- Discontinued (n=2)
- Adverse event (n=2)